JP2019508433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508433A5 JP2019508433A5 JP2018546036A JP2018546036A JP2019508433A5 JP 2019508433 A5 JP2019508433 A5 JP 2019508433A5 JP 2018546036 A JP2018546036 A JP 2018546036A JP 2018546036 A JP2018546036 A JP 2018546036A JP 2019508433 A5 JP2019508433 A5 JP 2019508433A5
- Authority
- JP
- Japan
- Prior art keywords
- liv
- adc
- subject
- pharmaceutical composition
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022006944A JP2022058676A (ja) | 2016-03-15 | 2022-01-20 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
| JP2024039750A JP2024075639A (ja) | 2016-03-15 | 2024-03-14 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308639P | 2016-03-15 | 2016-03-15 | |
| US62/308,639 | 2016-03-15 | ||
| US201662317792P | 2016-04-04 | 2016-04-04 | |
| US62/317,792 | 2016-04-04 | ||
| US201662367510P | 2016-07-27 | 2016-07-27 | |
| US62/367,510 | 2016-07-27 | ||
| PCT/US2017/022541 WO2017161007A1 (en) | 2016-03-15 | 2017-03-15 | Combination therapy using a liv1-adc and a chemotherapeutic |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022006944A Division JP2022058676A (ja) | 2016-03-15 | 2022-01-20 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019508433A JP2019508433A (ja) | 2019-03-28 |
| JP2019508433A5 true JP2019508433A5 (enExample) | 2020-04-23 |
Family
ID=59852409
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546036A Pending JP2019508433A (ja) | 2016-03-15 | 2017-03-15 | Ｌｉｖ１−ａｄｃ及び化学療法剤を用いた併用療法 |
| JP2022006944A Pending JP2022058676A (ja) | 2016-03-15 | 2022-01-20 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
| JP2024039750A Pending JP2024075639A (ja) | 2016-03-15 | 2024-03-14 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022006944A Pending JP2022058676A (ja) | 2016-03-15 | 2022-01-20 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
| JP2024039750A Pending JP2024075639A (ja) | 2016-03-15 | 2024-03-14 | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11325980B2 (enExample) |
| EP (1) | EP3429626A4 (enExample) |
| JP (3) | JP2019508433A (enExample) |
| KR (3) | KR20220157515A (enExample) |
| CN (1) | CN108697801A (enExample) |
| AU (2) | AU2017235545A1 (enExample) |
| BR (1) | BR112018068129A2 (enExample) |
| CA (1) | CA3016485A1 (enExample) |
| EA (1) | EA201891968A1 (enExample) |
| IL (1) | IL261505A (enExample) |
| MA (1) | MA45324A (enExample) |
| MX (2) | MX2018010847A (enExample) |
| SG (2) | SG10201912908QA (enExample) |
| WO (1) | WO2017161007A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3211246A1 (en) | 2010-12-06 | 2012-06-14 | Seagen Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
| EA202091360A1 (ru) * | 2017-12-01 | 2020-08-24 | Сиэтл Дженетикс, Инк. | Гуманизированные анти-liv1 антитела для лечения рака молочной железы |
| US12304968B2 (en) * | 2018-11-07 | 2025-05-20 | Crispr Therapeutics Ag | T-cells expressing anti-LIV1 chimeric antigen receptor |
| US20210228676A1 (en) * | 2019-12-09 | 2021-07-29 | Seagen Inc. | Combination Therapy With LIV1-ADC and PD-1 Antagonist |
| JP2023543026A (ja) * | 2020-09-28 | 2023-10-12 | シージェン インコーポレイテッド | がんの処置のためのヒト化抗ｌｉｖ１抗体 |
| WO2022198231A1 (en) | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| AU2024235054A1 (en) * | 2023-03-15 | 2025-10-02 | BioRay Pharmaceutical Co., Ltd. | Anti-liv-1 antibody and anti-liv-1 antibody-drug conjugate, and pharmaceutical use thereof |
| WO2025162207A1 (zh) * | 2024-01-31 | 2025-08-07 | 上海复宏汉霖生物技术股份有限公司 | 抗liv1抗体及使用方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| FI102355B1 (fi) | 1988-02-11 | 1998-11-30 | Bristol Myers Squibb Co | Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU663727B2 (en) | 1991-08-22 | 1995-10-19 | Becton Dickinson & Company | Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| CA2132500A1 (en) | 1994-09-20 | 1996-03-21 | David Lockwood Manning | Methods for predicting the behaviour of breast tumours |
| DE69626849T2 (de) | 1995-12-22 | 2003-12-24 | Bristol-Myers Squibb Co., Princeton | Verzweigte hydrazongruppen enthaltende kuppler |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| EP0939824B1 (en) | 1996-10-31 | 2007-06-06 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
| WO1998034118A1 (en) | 1997-01-30 | 1998-08-06 | Yale University | Diagnostic methods and compositions based on the distribution of rad51 |
| CA2308029A1 (en) | 1997-10-31 | 1999-05-14 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| WO1999025877A1 (en) | 1997-11-18 | 1999-05-27 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| JP2002507387A (ja) | 1997-12-24 | 2002-03-12 | コリクサ コーポレイション | 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法 |
| CA2347906A1 (en) | 1998-08-04 | 2000-02-17 | Diadexus, Inc. | A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| EP1953229A3 (en) | 1998-10-15 | 2008-12-24 | Novartis Vaccines and Diagnostics, Inc. | Metastatic breast and colon cancer regulated genes |
| AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| US6762020B1 (en) | 1999-03-15 | 2004-07-13 | Protein Design Labs, Inc. | Methods of diagnosing breast cancer |
| US20040141983A1 (en) | 1999-03-15 | 2004-07-22 | Protein Design Labs, Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
| EP1263780A2 (en) | 2000-01-25 | 2002-12-11 | Genentech, Inc. | Liv-1 related protein, polynulceotides encoding the same and use thereof for treatment of cancer |
| AU2001264099A1 (en) | 2000-06-13 | 2001-12-24 | University College Cardiff Consultants Ltd. | Zinc transporters |
| US6964849B2 (en) | 2001-01-11 | 2005-11-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003000012A2 (en) | 2001-06-21 | 2003-01-03 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer |
| AU2002322280A1 (en) | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| WO2003075855A2 (en) | 2002-03-08 | 2003-09-18 | Protein Design Labs, Inc. | Antibodies against cancer antigen tmeff2 and uses thereof |
| JP4741838B2 (ja) | 2002-07-31 | 2011-08-10 | シアトル ジェネティクス，インコーポレーテッド | 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用 |
| MXPA05007940A (es) | 2003-01-27 | 2007-06-14 | Biogen Idec Inc | Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1. |
| WO2004067564A2 (en) | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
| CN104998273A (zh) | 2003-11-06 | 2015-10-28 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| WO2005058961A2 (en) | 2003-12-12 | 2005-06-30 | Amgen Inc. | Antibodies specific for human galanin, and uses thereof |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| US20060222653A1 (en) | 2004-11-12 | 2006-10-05 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| KR20080080482A (ko) * | 2005-09-07 | 2008-09-04 | 메디뮨 엘엘씨 | 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체 |
| CN101309933A (zh) * | 2005-09-07 | 2008-11-19 | 米迪缪尼有限公司 | 毒素偶联的Eph受体抗体 |
| CN101622273A (zh) | 2006-04-13 | 2010-01-06 | 诺瓦提斯疫苗和诊断公司 | 治疗、诊断或检测与liv-1过量表达相关的癌症的方法 |
| PT2099823E (pt) | 2006-12-01 | 2014-12-22 | Seattle Genetics Inc | Agentes de ligação ao alvo variantes e suas utilizações |
| RU2009140134A (ru) | 2007-04-23 | 2011-05-27 | Вайет (Us) | Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений |
| EP2615115A3 (en) | 2007-11-30 | 2014-01-08 | Glaxo Group Limited | Antigen-binding constructs |
| EP2304631A1 (en) | 2008-06-16 | 2011-04-06 | Sividon Diagnostics GmbH | Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer |
| US20110195995A1 (en) | 2008-10-14 | 2011-08-11 | Wittliff James L | Methods of Optimizing Treatment of Estrogen-Receptor Positive Breast Cancers |
| WO2010069858A1 (en) | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| US20110165566A1 (en) | 2009-07-09 | 2011-07-07 | Wittliff James L | Methods of optimizing treatment of breast cancer |
| MX2012002766A (es) | 2009-09-03 | 2012-04-02 | Genentech Inc | Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. |
| CA3211246A1 (en) | 2010-12-06 | 2012-06-14 | Seagen Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
| WO2012125712A2 (en) | 2011-03-14 | 2012-09-20 | Respira Health, Llc | Lung tumor classifier for current and former smokers |
| WO2013055874A2 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| WO2013170263A2 (en) | 2012-05-11 | 2013-11-14 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics |
| DE202012006349U1 (de) | 2012-07-03 | 2013-07-05 | Schuster Engineering Gmbh | Schiffsladeanordnung |
| DK2839860T3 (da) * | 2012-10-12 | 2019-06-17 | Medimmune Ltd | Pyrrolobenzodiazepiner og konjugater deraf |
| US10898555B2 (en) | 2013-07-02 | 2021-01-26 | Japanese Foundation For Cancer Research | Cellular immunity inducing vaccine |
| EP3130608B1 (en) | 2014-04-10 | 2019-09-04 | Daiichi Sankyo Co., Ltd. | (anti-her2 antibody)-drug conjugate |
| EA202091360A1 (ru) * | 2017-12-01 | 2020-08-24 | Сиэтл Дженетикс, Инк. | Гуманизированные анти-liv1 антитела для лечения рака молочной железы |
| US12304968B2 (en) | 2018-11-07 | 2025-05-20 | Crispr Therapeutics Ag | T-cells expressing anti-LIV1 chimeric antigen receptor |
| GB201908208D0 (en) | 2019-06-10 | 2019-07-24 | Univ College Cardiff Consultants Ltd | An anti-mitotic agent |
| US20210228676A1 (en) | 2019-12-09 | 2021-07-29 | Seagen Inc. | Combination Therapy With LIV1-ADC and PD-1 Antagonist |
-
0
- MA MA045324A patent/MA45324A/fr unknown
-
2017
- 2017-03-15 WO PCT/US2017/022541 patent/WO2017161007A1/en not_active Ceased
- 2017-03-15 KR KR1020227039721A patent/KR20220157515A/ko not_active Ceased
- 2017-03-15 SG SG10201912908QA patent/SG10201912908QA/en unknown
- 2017-03-15 BR BR112018068129A patent/BR112018068129A2/pt active Search and Examination
- 2017-03-15 KR KR1020187028273A patent/KR20180121571A/ko not_active Ceased
- 2017-03-15 CN CN201780013873.8A patent/CN108697801A/zh active Pending
- 2017-03-15 MX MX2018010847A patent/MX2018010847A/es unknown
- 2017-03-15 SG SG11201807526SA patent/SG11201807526SA/en unknown
- 2017-03-15 EP EP17767448.8A patent/EP3429626A4/en active Pending
- 2017-03-15 JP JP2018546036A patent/JP2019508433A/ja active Pending
- 2017-03-15 KR KR1020237041743A patent/KR20230169462A/ko not_active Withdrawn
- 2017-03-15 US US16/085,511 patent/US11325980B2/en active Active
- 2017-03-15 CA CA3016485A patent/CA3016485A1/en active Pending
- 2017-03-15 EA EA201891968A patent/EA201891968A1/ru unknown
- 2017-03-15 AU AU2017235545A patent/AU2017235545A1/en not_active Abandoned
-
2018
- 2018-09-02 IL IL261505A patent/IL261505A/en unknown
- 2018-09-07 MX MX2023008849A patent/MX2023008849A/es unknown
-
2022
- 2022-01-20 JP JP2022006944A patent/JP2022058676A/ja active Pending
- 2022-10-17 US US18/047,243 patent/US20230235083A1/en not_active Abandoned
-
2024
- 2024-03-14 JP JP2024039750A patent/JP2024075639A/ja active Pending
- 2024-03-21 AU AU2024201856A patent/AU2024201856A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019508433A5 (enExample) | ||
| Glassman et al. | Mechanistic considerations for the use of monoclonal antibodies for cancer therapy | |
| Liao et al. | Model‐informed therapeutic dose optimization strategies for antibody–drug conjugates in oncology: what can we learn from US Food and Drug Administration–approved antibody–drug conjugates? | |
| JP6177133B2 (ja) | Ｃｄ３８を特異的に認識する抗体とボルテゾミブを含有する抗腫瘍性の組合せ | |
| Koga et al. | Antitumor effect of antitissue factor antibody‐MMAE conjugate in human pancreatic tumor xenografts | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| US20230235083A1 (en) | Combination therapy using a liv1-adc and a chemotherapeutic | |
| JP2018522850A5 (enExample) | ||
| JP2019516748A5 (enExample) | ||
| RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
| JP2016520082A5 (enExample) | ||
| HRP20151172T1 (hr) | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka | |
| JP2019517505A5 (enExample) | ||
| JP2019503387A5 (enExample) | ||
| CA3093731A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| JP2021501776A5 (enExample) | ||
| WO2011101328A3 (en) | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor | |
| CN102448497A (zh) | 在癌症治疗中的西仑吉肽的持续给药 | |
| JP2019524713A5 (enExample) | ||
| Chakraborty et al. | A phase 1, open-label, dose-escalation study of the safety and efficacy of anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma | |
| KR20210084560A (ko) | Pd-1/pd-l1 신호전달 억제제에 반응하지 않는 암을 치료하기 위한 방법 및 약제 | |
| Pretelli et al. | Antibody-drug conjugates combinations in cancer treatment | |
| Richardson et al. | Antibody drug conjugates in the treatment of epithelial ovarian cancer | |
| Hu et al. | Review of dose justifications for antibody-drug conjugate approvals from clinical pharmacology perspective: A focus on exposure-response analyses | |
| Grimsley et al. | Monoclonal antibodies in cancer |